NASDAQ
SRTA
Last Price
US $5.97
Valuation
Financial
Performance
Cash flow to debt coverage
Strata Critical Medical, Inc. cash flow to debt ratio of -1.48K% indicates that the company cannot generate enough cash to cover its debt over time. This level indicates weak financial health.
Free cash flow growth
Strata Critical Medical, Inc.'s free cash flow has decreased 68.74% from $-35.51M last year to $-59.92M, signaling decreasing performance
Debt-to-equity ratio
Strata Critical Medical, Inc.'s debt to equity ratio is 0.02, which means that the company's assets are healthy financed, signaling financial stability.
Debt-to-equity trend
Strata Critical Medical, Inc.'s debt has decreased relative to shareholder equity from 0.04 last year to 0.02 today, signaling strengthened financials
Net debt to EBITDA
Strata Critical Medical, Inc. has a net cash position, so leverage is healthy.
Interest coverage
Strata Critical Medical, Inc. earns at least as much interest as it pays. Interest obligations are fully covered.
Profit margin growth
Strata Critical Medical, Inc.'s profit margin has increased (-243.10%) in the last year from -10.98% to 15.71%, signaling increasing performance
Current ratio
Strata Critical Medical, Inc.'s short-term assets of $126.19M exceed its short-term liabilities of $19.79M
Return on assets
Strata Critical Medical, Inc.'s return on assets of 12.09% is higher than the 5.00% threshold, indicating efficient asset utilization
Return on equity
Strata Critical Medical, Inc.'s return on equity of 14.27%, is lower than 15.00%, indicating bad performance
Earnings quality
Strata Critical Medical, Inc.'s operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation
Earnings stability
Strata Critical Medical, Inc. had positive net income in only 1 out of 5 years, indicating unstable earnings
Positive free cash flow
Strata Critical Medical, Inc. has negative free cash flow, indicating the company is burning cash rather than generating it
Free cash flow yield
Strata Critical Medical, Inc. has negative free cash flow, indicating cash burn
Earnings growth
Strata Critical Medical, Inc.'s yearly earnings has increased -251.42% since last year from $-27.31M to $41.35M, signaling increasing performance
Revenue growth
Strata Critical Medical, Inc.'s yearly revenue has decreased 20.73% since last year from $248.69M to $197.14M, signaling decreasing performance
Return on invested capital
ROIC -7.09% (Source: FMP key-metrics). Below the 5% partial-credit threshold. Score: 0 of 2. The 5% and 10% cutoffs anchor to typical US weighted-average cost of capital. Below 5% indicates the company is not generating returns above its likely cost of capital under this definition of invested capital. Invested capital here includes equity, non-current liabilities (pension obligations, deferred taxes, lease obligations), and short-term debt. Cash is not subtracted. Companies with substantial float, lease portfolios, or cash holdings will score lower under this definition than under narrower operating-capital definitions. See methodology.
3-year revenue CAGR
Strata Critical Medical, Inc.'s 3-year revenue CAGR of 10.50% is positive, indicating growing revenue over the past 3 years
Revenue consistency
Strata Critical Medical, Inc. had revenue growth in 4 out of 5 years, indicating consistent revenue performance
Return on equity consistency
Strata Critical Medical, Inc. had positive ROE in only 1 out of 5 years, indicating inconsistent returns on equity
Cash Flow Valuation (DCF)
Strata Critical Medical, Inc. has insufficient data to evaluate this check.
Earnings yield (TTM)
Strata Critical Medical, Inc. has an earnings yield of 7.85%, which is above the 4.00% threshold, indicating the stock offers reasonable value relative to its earnings
EBITDA Valuation
Strata Critical Medical, Inc. is overvalued relative to its fair value price of 0.00 based on EBITDA multiple model
EV/EBITDA (FY)
Strata Critical Medical, Inc. has negative or missing EBITDA, making EV/EBITDA ratio unreliable
PEG ratio (TTM/FY)
Strata Critical Medical, Inc. had non-positive diluted EPS five years ago; the PEG ratio is not meaningful and the check fails.
Price-to-book ratio (FY)
Strata Critical Medical, Inc. has a price-to-book ratio of 1.83x, which is below the 5.00x threshold, indicating reasonable valuation relative to its book value
Price-to-sales ratio (TTM)
Strata Critical Medical, Inc. has a price-to-sales ratio of 2.00x, which is below the 8.00x threshold, indicating reasonable valuation relative to its revenue
Profit margin
Current Ratio
Capital Returns
14.27%
Return on equity
ROIC: -7.09%
Valuation History
12.0X
Price to Earnings
EV/EBITDA: -53.9X
Cash flow
Profit margin
11.49%
Cash flow
-28.50%
Fair Value
Market $5.97
—
Default assumptions
Base valuations use default assumptions. Customize in the Valuator.